Kriba

Kriba® is a medical device startup aiming at globally democratizing non-invasive, quick, easy and cost-efficient screening and monitoring of potentially life-threatening extravascular serous fluids infections like infant meningitis, peritoneal dialysis-associated peritonitis, anterior uveitis, among others. Located in the Barcelona Science Park in Spain, Kriba has developed Neosonics® and Neosonics® Vitro Kidney, an AI-powered ultrasound device for quick and rapid screening and monitoring of serous fluids infections. Kriba Kidney's aim is to advance peritoneal dialysis-associated peritonitis early detection. Neosonics® Vitro Kidney is an automatic, compact, quick, easy-to-use device that non-invasively determines effluent white blood cell levels and differential on the drainage bag. Neosonics Vitro Kidney will support clinical decision-making for early detection and prevention of peritonitis complications. The aim is to implement a home-based system. Kriba Newborn drives infant meningitis screening and monitoring. Neosonics® is a non-invasive and automatic transfontanellar cerebrospinal fluid white blood cell counter for newborns and infants meningitis screening and monitoring, to reduce negative lumbar punctures and democratize access to early detection around the world. Kriba Eye care is dedicated to anterior uveitis screening, monitoring, and objective quantification. Neosonics® and Neosonics© Vitro Kidney are under development. It is not for sale. This device has not yet been approved by the FDA or CE marking authorities. This project has been funded by the European Union's Horizon Europe research and innovation programme. As a result, this collaboration is subjected to the rules stated in Grant Agreement 190155553 - NEOSONICS between the European Innovation Council and Newborn Solutions that are available upon request.